| P50 | author | Alberto M Martelli | Q56922777 |
| | Jörg Baesecke | Q69033710 |
| | Ferdinando Nicoletti | Q84521195 |
| | Linda S Steelman | Q114723345 |
| | Franca Stivala | Q114723350 |
| | Stephen L Abrams | Q123366731 |
| | William H Chappell | Q123366743 |
| | Massimo Libra | Q37842996 |
| | Marco Donia | Q40146733 |
| | James A. McCubrey | Q42317570 |
| P2093 | author name string | Ellis W T Wong | |
| | John G Shelton | |
| P2860 | cites work | Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance | Q24645668 |
| | DNA damage-induced cell death is enhanced by progression through mitosis | Q30495277 |
| | Targeting signal transduction pathways to eliminate chemotherapeutic drug resistance and cancer stem cells. | Q33823577 |
| | Multiple p53-independent gene silencing mechanisms define the cellular response to p53 activation | Q34080682 |
| | Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia. | Q36461618 |
| | Program-like aging and mitochondria: instead of random damage by free radicals | Q36988252 |
| | Targeting prostate cancer based on signal transduction and cell cycle pathways. | Q36995054 |
| | PI3K/mTORC1 activation in hamartoma syndromes: therapeutic prospects | Q37032524 |
| | Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. | Q37109225 |
| | Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. | Q37109227 |
| | At concentrations that inhibit mTOR, resveratrol suppresses cellular senescence. | Q45995695 |
| | Aging-suppressants: cellular senescence (hyperactivation) and its pharmacologic deceleration. | Q46008332 |
| | Cancer and aging: more puzzles, more promises? | Q46417167 |
| | Involvement of p53 and Raf/MEK/ERK pathways in hematopoietic drug resistance | Q46441674 |
| | The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T-acute leukemia cells by a JNK-dependent mechanism | Q46666883 |
| | Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells | Q46956224 |
| | Genomic instability en route to and from cancer stem cells. | Q53312262 |
| | Differential effects of retroviral long terminal repeats on interleukin-3 gene expression and autocrine transformation. | Q53440045 |
| | Resist or die: FOXO transcription factors determine the cellular response to chemotherapy. | Q53446661 |
| | The insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 induces apoptosis in acute myeloid leukemia cells exhibiting autocrine insulin-like growth factor-I secretion | Q56995355 |
| | Abrogation of factor-dependence in two IL-3-dependent cell lines can occur by two distinct mechanisms | Q69738450 |
| | PI-PLCbeta-1 and activated Akt levels are linked to azacitidine responsiveness in high-risk myelodysplastic syndromes | Q80599609 |
| | Cancer stem cell and cancer stemloids: from biology to therapy | Q37111467 |
| | Cancer stem cells and survival pathways | Q37141755 |
| | PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches | Q37192606 |
| | Aging, stem cells, and mammalian target of rapamycin: a prospect of pharmacologic rejuvenation of aging stem cells | Q37253119 |
| | Targeting the leukemic stem cell: the Holy Grail of leukemia therapy | Q37272565 |
| | Aging: ROS or TOR. | Q37312907 |
| | Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors. | Q37331720 |
| | Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia | Q37331742 |
| | Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitors | Q37355543 |
| | Targeting mTOR with rapamycin: one dose does not fit all | Q37409171 |
| | Enrichment of hematopoietic precursor cells and cloning of multipotential B-lymphocyte precursors | Q37554117 |
| | Mutant p53 rescue and modulation of p53 redox state. | Q37562710 |
| | The p53 tumor suppressor protein is a critical regulator of hematopoietic stem cell behavior | Q37597839 |
| | Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation | Q38290400 |
| | Specific activation of the p53 pathway by low dose actinomycin D: a new route to p53 based cyclotherapy. | Q39816293 |
| | Pharmacologic inhibition of MEK and PI-3K converges on the mTOR/S6 pathway to decelerate cellular senescence | Q39845659 |
| | Rapamycin decelerates cellular senescence | Q39846812 |
| | The transcription-independent mitochondrial p53 program is a major contributor to nutlin-induced apoptosis in tumor cells | Q39857411 |
| | Upregulation of the CDC25A phosphatase down-stream of the NPM/ALK oncogene participates to anaplastic large cell lymphoma enhanced proliferation. | Q39869731 |
| | Growth stimulation leads to cellular senescence when the cell cycle is blocked | Q39925937 |
| | Phosphoinositide 3-kinase signaling overrides a G2 phase arrest checkpoint and promotes aberrant cell cycling and death of hematopoietic cells after DNA damage. | Q39943580 |
| | c-Jun N-terminal kinase activation failure is a new mechanism of anthracycline resistance in acute myeloid leukemia | Q39957937 |
| | BH3 activation blocks Hdmx suppression of apoptosis and cooperates with Nutlin to induce cell death | Q39964587 |
| | The role of the PTEN/AKT Pathway in NOTCH1-induced leukemia | Q39991646 |
| | Dual inhibition of PI3K/Akt signaling and the DNA damage checkpoint in p53-deficient cells with strong survival signaling: implications for cancer therapy | Q40077070 |
| | Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts | Q40184405 |
| | Synergy between an IGF-1R antibody and Raf/MEK/ERK and PI3K/Akt/mTOR pathway inhibitors in suppressing IGF-1R-mediated growth in hematopoietic cells. | Q40287051 |
| | P21(Cip1) induced by Raf is associated with increased Cdk4 activity in hematopoietic cells. | Q40790669 |
| | Malignant transformation induced by cytokine genes: a comparison of the abilities of germline and mutated interleukin 3 genes to transform hematopoietic cells by transcriptional and posttranscriptional mechanisms | Q41207196 |
| | Synergy between AUUUA motif disruption and enhancer insertion results in autocrine transformation of interleukin-3-dependent hematopoietic cells | Q41282247 |
| | The CML stem cell: evolution of the progenitor | Q42135962 |
| | RHAMM is differentially expressed in the cell cycle and downregulated by the tumor suppressor p53. | Q42807099 |
| | Enhancement of cancer chemotherapy by simultaneously altering cell cycle progression and DNA-damage defenses through global modification of the serine/threonine phospho-proteome | Q43266699 |
| | Effects of the RAF/MEK/ERK and PI3K/AKT signal transduction pathways on the abrogation of cytokine-dependence and prevention of apoptosis in hematopoietic cells. | Q44419395 |
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | drug resistance | Q12147416 |
| | apoptotic process | Q14599311 |
| P1104 | number of pages | 11 | |
| P304 | page(s) | 1781-1791 | |
| P577 | publication date | 2010-05-10 | |
| P1433 | published in | Cell Cycle | Q1254166 |
| P1476 | title | The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy | |
| P478 | volume | 9 | |